Overview of the international myeloma workshop 2013 Kyoto

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 1, 2014, Pages 2-4

  Shimizu, Kazuyuki ^a  

^a Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN A; LACTATE DEHYDROGENASE; M PROTEIN; THALIDOMIDE;

ASIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; JAPAN; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; WORKSHOP;

HUMANS; MULTIPLE MYELOMA;

EID: 84892747892     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.12.007     Document Type: Note

References (18)

1. A. Orfao, B. Paiva, and M.B. Vidriales et al. What is the best surrogate marker for long-term survival in multiple myeloma, sCR, iCR, mCR or PET/CT? Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S7 S11
2. E. Zamagni Usefulness of newer imaging techniques as predictor of outcomes in MM - Comparisonbetween PET/CT and MRI in different settings Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S6 S11
3. H. Avet-Liseau Risk assessment Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S9 S11
4. S.V. Rajkumar Debate: Induction therapy: risk-adapted, response-adapted, or one size fits all strategy Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S9 S12
5. P. Sonneveld Debate: Induction therapy: risk-adapted, response-adapted, or one size fits all Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S9 S13
6. A. Palumbo Tailoring multiple myeloma therapy for special populations Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S1 S4
7. P. Moreau, and P.G. Richardson Debate: Early or delayed transplantation for multiple myeloma in the era of novel therapies: does one size fit all? Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S9 S14
8. M. Cavo What is the role of post-transplant consolidation therapy? Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S15 S21
9. A. Spencer What is the optimal duration of maintenance therapy? Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S15 S24
10. P. MaCarthy, K. Owzar, and C. Hofmeister et al. Analysis of overall survival (OS) in the context of cross-over from placebo to lenalidomide and the incidence of second primary malignancies (SPM) in the phase III study of lenalidomide versus placebo maintenance therapy following autologous stem cell transplant (ASCT) for multiple myeloma (MM) CALGB (alliance) ECOG BMT-CTN 100104 Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S15 S25
11. L.M. Pilarski Clonal dynamics in multiple myeloma Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S3 S4
12. M.V. Mateos, and J. San Miguel Should we treat smoldering multiple myeloma? Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S11 S13
13. O. Landgren The molecular pathway to myeloma Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S11 S21
14. N. Munshi, and J.P. Fermand Smoldering MM in 2013: "To treat or not to treat"?] Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S11 S14
15. P.G. Richardson, J. Laubach, and D. Chauhan et al. Extending treatment options for patients with advanced MM and optimizing the management of relapsed and refractory disease Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S14 S24
16. J.H. Lee Report from Asian Myeloma Network (AMN) Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S16 S21
17. M. Iwanaga, and M. Tomonaga MGUS prevalence among Nagasaki Atomic Bomb survivors Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S16 S23
18. K. Suzuki Showcase Japan - Histories and trials Clin Lymphoma Myeloma Leuk 13 suppl 1 2013 S16 S24